Table of Contents

• 1.   Market Introduction
  •   1. Objectives of the Study
      2. Market Definition
      3. Market Scope
       3.1 . Years Considered for the Study
       3.2 . Market Covered
      4. Currency
      5. Limitations
      6. Stakeholders
    
• 2.   Research Methodology
  •   1. Research Data
       1.1 . Secondary Data
        1.1.1 . Key Data from Secondary Sources
       1.2 . Primary Data
        1.2.1. Key Data from Primary Sources
      2. Market Size Estimation
      3. Market Breakdown and Data Triangulation
      4. Assumptions for the Study
    
• 3.   Executive Summary
  •   1. Market Outlook
      2. Segment Outlook
      3. Competitive Insights
    
• 4.   North America Liver Disease Treatment Market Variables, Trends and Scope

  •   1. Market Lineage Outlook
      2. Penetration and Growth Prospect Mapping
      3. Industry Value Chain Analysis
      4. Cost Analysis Breakdown
      5. Technology Overview
      6. Regulatory Framework
       6.1. Reimbursement Framework
       6.2. Standards and Compliances

• 5.   Market Overview
  •   1. Market Dynamics
       1.1. Market Driver Analysis
        1.1.1. Increasing focus of North America Liver Disease Treatment Companies on Brand Protection
        1.1.2. Untapped Opportunities in Emerging Regions
       1.2. Market Restraint Analysis
        1.2.1. High Cost Associated with Implementation of Predictive Analysis
       1.3. Industry Challenges
        1.3.1. Presence of Ambiguous Regulatory Framework
    
• 6.   North America Liver Disease Treatment Market Analysis Tools
  •   1. Industry Analysis - Porter’s
       1.1. Supplier Power
       1.2. Buyer Power
       1.3. Substitution Threat
       1.4. Threat from New Entrants
       1.5. Competitive Rivalry
      2. Pestel Analysis
       2.1. Political Landscape
       2.2. Environmental Landscape
       2.3. Social Landscape
       2.4. Technology Landscape
       2.5. Legal Landscape
      3. Major Deals And Strategic Alliances Analysis
       3.1. Joint Ventures
       3.2. Mergers and Acquisitions
       3.3. Licensing and Partnership
       3.4. Technology Collaborations
       3.5. Strategic Divestments
      4. Market Entry Strategies
      5. Case Studies
    
• 7.   North America Liver Disease Treatment Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Antiviral Drugs
      2. Immunosuppressants
      3. Vaccines
      4. Immunoglobulins
      5. Corticosteroids
      6. Targeted Therapy
      7. Chemotherapy

• 8.   North America Liver Disease Treatment Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Hepatits
      2. Autoimmune Diseases
      3. Ischemic Stroke
      4. Stenosis
      5. Others

• 9.   North America Liver Disease Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

  •   1. Introduction
      2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
       2.1. U.S.A
       2.2. Canada
       2.3. Mexico
      3. Market Size (USD Million) Forecast for North America 2023-2031

• 10.   Market Share Analysis and Competitive Landscape
  •   1. North America Landscape - Key Players, Revenue and Presence
      2. North America Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
      3. North America Emerging Companies
      4. North America - Market Share Analysis and Key Regional Players
      5. North America Key Player - Growth Matrix
    
• 11.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

  •   1. ABBVIE INC.
       1.1. Company Overview
       1.2. Product Portfolio
       1.3. SWOT Analysis
       1.4. Financial Overview
       1.5. Strategic Overview
      2. ASTELLAS PHARMA INC.
       2.1. Company Overview
       2.2. Product Portfolio
       2.3. SWOT Analysis
       2.4. Financial Overview
       2.5. Strategic Overview
      3. BRISTOL-MYERS SQUIBB COMPANY
       3.1. Company Overview
       3.2. Product Portfolio
       3.3. SWOT Analysis
       3.4. Financial Overview
       3.5. Strategic Overview
      4. DYNAVAX TECHNOLOGIES CORPORATION
       4.1. Company Overview
       4.2. Product Portfolio
       4.3. SWOT Analysis
       4.4. Financial Overview
       4.5. Strategic Overview
      5 . ELI LILY AND COMPANY
       5.1. Company Overview
       5.2. Product Portfolio
       5.3. SWOT Analysis
       5.4. Financial Overview
       5.5. Strategic Overview
      6 . EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA)
       6.1. Company Overview
       6.2. Product Portfolio
       6.3. SWOT Analysis
       6.4. Financial Overview
       6.5. Strategic Overview
      7. GILEAD SCIENCES, INC.
       7.1. Company Overview
       7.2. Product Portfolio
       7.3. SWOT Analysis
       7.4. Financial Overview
       7.5. Strategic Overview
      8. MERCK & Co. INC.
       8.1. Company Overview
       8.2. Product Portfolio
       8.3. SWOT Analysis
       8.4. Financial Overview
       8.5. Strategic Overview
      9. MYLAN N.V.
       9.1. Company Overview
       9.2. Product Portfolio
       9.3. SWOT Analysis
       9.4. Financial Overview
       9.5. Strategic Overview
      10. PFIZER INC. (PHARMACIA CORPORATION)
       10.1. Company Overview
       10.2. Product Portfolio
       10.3. SWOT Analysis
       10.4. Financial Overview
       10.5. Strategic Overview

• 12.   Pre and Post COVID-19 Impact
  •   1. Positive influence on the healthcare industry
      2. The financial disruption of the manufacturing sector
      3. Impact of COVID-19 on emerging companies
      4. Significant mandates in the healthcare regulations initiated by administrations
      5. The overall economic slowdown of the developing and developed nations
    
• 13.   FutureWise SME Key Takeaway Points for Client